Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer.
about
Mutational analysis of the N-terminal DNA-binding domain of sleeping beauty transposase: critical residues for DNA binding and hyperactivity in mammalian cellsA transposon and transposase system for human applicationThe Sleeping Beauty transposon system: a non-viral vector for gene therapyPreferential delivery of the Sleeping Beauty transposon system to livers of mice by hydrodynamic injectionGenerating and manipulating transgenic animals using transposable elementsAdvances in understanding and treating dystrophic epidermolysis bullosaNovel therapeutic approaches for various cancer types using a modified sleeping beauty-based gene delivery systemDNA transposon-based gene vehicles - scenes from an evolutionary driveRole of protein tyrosine phosphatases in cancerHigh-resolution genome-wide mapping of transposon integration in mammals.Increased interstitial pressure improves nucleic acid delivery to skin enabling a comparative analysis of constitutive promoters.Gene expression in lung and liver after intravenous infusion of polyethylenimine complexes of Sleeping Beauty transposons.Hybrid lentivirus-transposon vectors with a random integration profile in human cells.Translating Sleeping Beauty transposition into cellular therapies: victories and challenges.Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo.Keratin gene mutations in disorders of human skin and its appendages.Strategies for long-term gene expression in the skin to treat metabolic disorders.Gene therapy of epidermolysis bullosa.AAV-mediated gene targeting is significantly enhanced by transient inhibition of nonhomologous end joining or the proteasome in vivoPredicting preferential DNA vector insertion sites: implications for functional genomics and gene therapy.Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity.Gene therapy in combination with tissue engineering to treat epidermolysis bullosa.Strategies to improve non-viral vectors--potential applications in clinical transplantation.Gene therapy progress and prospects: the skin--easily accessible, but still far away.From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa.Cutaneous gene therapy.An approach to achieve long-term expression in skin gene therapy.Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies.Recent developments in transposon-mediated gene therapy.The long and winding road that leads to a cure for epidermolysis bullosa.Efficient non-viral integration and stable gene expression in multipotent adult progenitor cells.Next generation human skin constructs as advanced tools for drug development.Somatic correction of junctional epidermolysis bullosa by a highly recombinogenic AAV variant.Sleeping Beauty transposition: from biology to applications.Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side.Immortalized keratinocytes derived from patients with epidermolytic ichthyosis reproduce the disease phenotype: a useful in vitro model for testing new treatments.Preclinical and clinical advances in transposon-based gene therapy.
P2860
Q24561411-BDC54689-A0D9-4D87-83C4-B7423590E89BQ24630047-76FA23AF-0C40-4B42-AEDC-7DA0F9955C88Q24633847-F47B0949-8ADF-4D3B-8044-281742CCAA3AQ24646028-08AC593B-50E2-4F83-9A9A-5E1923954AABQ24798528-7AFA9219-A88D-4DAE-8CD1-6D5475E1DB28Q27006669-277B102D-6F0C-45E4-81D3-49559B112D58Q28660424-295AA231-FC08-4488-AA7A-E3399F78A35AQ28660891-5A71C646-B5B9-4C45-BDD2-65A3D459BAC8Q28741003-AF1C81B9-CEBF-4050-B34A-8003F1EFCB0CQ28769896-F99906FA-5EB3-46ED-A38E-2AFE4D4A438FQ33576601-D713EA61-CF87-4641-8ED4-998CD1E3DBC6Q33691825-862D0A8B-7DDB-4656-A82A-472483C3868FQ33713812-02408AD6-F641-4E84-9AF6-1CA2A7135C7EQ34127579-8C02AC96-59D6-44AC-903C-4282ADE718C6Q35105022-683DF822-7D33-4A3F-928D-31B7079DA2A5Q35125858-2F0928DF-7A72-4EF3-BB0D-BFBBC59D1B74Q35779369-D321D043-E1AD-46E8-9D88-C3B9419ACF2FQ35873767-BB22821F-2586-4A11-82E0-DA20070F2ED1Q36084471-F3E6E636-4A99-4152-80F7-45E0BC15903EQ36187534-4E8C66EC-3B0A-46D4-9EF9-C2426E9CF5B3Q36311669-BB7709AE-F38F-4F5A-A3BA-ACBFD0BD9101Q36425931-6AD5FC32-4DCD-42B8-B968-933D66E3CCDBQ36481006-00284EC3-80FA-4D8E-89AC-3DECFD41E83FQ36587586-B19D4A1D-D325-45A8-94D4-78FA35E79FBEQ36756725-536527C2-FCBE-4CBD-A17F-35891C7DCDEEQ36799389-F4CBD95C-CC0E-4238-98B7-BD4FF10720BAQ37109093-EBCB45B4-33FC-42B9-A846-ACA46DA05D14Q37925857-840CBB9C-1C1D-4735-AE7D-6F2B7C3AEE2FQ38017202-CC68D8B0-1631-42A7-8C1C-11230E2BAEACQ38119245-D93E2EC0-366A-4856-A688-555F97D9A974Q38603168-E7B085C6-60DA-4E37-8813-6BCD033BFFF0Q38673576-CB5BBE7D-8D7F-4B37-932A-895FC4A158F5Q38692453-366F3422-7027-4E15-8F18-38D2A273D35DQ38970768-88BB895A-6F32-4812-9A0C-CB74833B1696Q39237421-F2D76A41-055D-417A-BAAD-6F567178499CQ39639706-DE81B637-AF73-4F87-9177-59C67E406EADQ45873802-9C2E6BAD-FC14-499E-8671-8B877476CB96
P2860
Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Sustainable correction of junc ...... diated nonviral gene transfer.
@en
Sustainable correction of junc ...... diated nonviral gene transfer.
@nl
type
label
Sustainable correction of junc ...... diated nonviral gene transfer.
@en
Sustainable correction of junc ...... diated nonviral gene transfer.
@nl
prefLabel
Sustainable correction of junc ...... diated nonviral gene transfer.
@en
Sustainable correction of junc ...... diated nonviral gene transfer.
@nl
P2093
P2860
P356
P1433
P1476
Sustainable correction of junc ...... diated nonviral gene transfer.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.GT.3301978
P577
2003-07-01T00:00:00Z
P5875
P6179
1015719203